Intranasal Administration of an Arginine‐Enriched Penetratin Peptide Confers Neuroprotection via Mitochondrial Functional Modulation in a Genetic Parkinson's Disease Model
CNS Neuroscience & Therapeutics · 2026-08 · 32 (8)
DOI: 10.1002/cns.71108 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 26.08.2026. Verfasst von Jui-Chih Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center of Regenerative Medicine and Tissue Repair, Institute of ATP, Changhua Christian Hospital, Changhua, Taiwan. Hauptthemen laut MEDLINE: Mitochondria, Cell-Penetrating Peptides, Neuroprotective Agents, Arginine. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Changhua Christian Hospital.
Abstract (Originalsprache)
Background
Mitochondrial dysfunction is a central pathogenic mechanism in Parkinson's disease (PD), particularly in genetic forms associated with respiratory chain impairment. Disease‐modifying therapies capable of restoring neuronal bioenergetics while achieving non‐invasive brain delivery remain lacking. This study investigated the therapeutic potential of an arginine‐enriched penetratin‐derived peptide (PenArg) in a genetic PD model carrying the UQCRC1 (p.Tyr314Ser) mutation.
Methods
The effects of PenArg labeled with 5‐FAM– or biotin were evaluated in UQCRC1 knock‐in SH‐SY5Y cells and mice. Mitochondrial function, neuronal survival, and apoptosis were assessed using biochemical and imaging analyses. Brain distribution was evaluated 2 h after intranasal administration, and therapeutic efficacy was examined following chronic intranasal treatment (three times weekly for six months).
Results
PenArg restored mitochondrial membrane potential, improved neuronal viability, and reduced oxidative stress‐induced apoptosis in cellular models. Imaging studies demonstrated partial mitochondrial localization in vitro and in vivo. Intranasal administration significantly improved locomotor performance, preserved dopaminergic neurons in the substantia nigra (SN) and striatum, and maintained hippocampal neuronal structure. Brain distribution analysis confirmed widespread brain penetration after intranasal administration. PenArg restored ATP synthase subunit beta expression and complex III activity while reducing cytochrome c release and caspase‐3 activation in SN neurons. Treatment additionally attenuated skeletal muscle atrophy, enhanced antioxidant responses, and reduced circulating pro‐inflammatory cytokines.
Conclusion
PenArg confers neuroprotection through functional modulation of mitochondrial homeostasis and produces multisystem therapeutic benefits. Intranasal administration represents a non‐invasive strategy with disease‐modifying potential for mitochondrial‐related neurodegenerative disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Regenerative Medicine and Tissue Repair, Institute of ATP, Changhua Christian Hospital, Changhua, Taiwan.
- Department of Nutrition, Chung Shan Medical University, Taichung, Taiwan.
- Department of Nutrition, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Laboratory Animal Center, Changhua Christian Hospital, Changhua, Taiwan.
- Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
- Vascular and Genomic Center, Institute of ATP, Changhua Christian Hospital, Changhua, Taiwan.
ORCID-Profile: Jui-Chih Chang, Chin-Hsien Lin, Chin-San Liu
Förderung
- National Science and Technology Council
- Changhua Christian Hospital
Zitieren
APA
Chang, J. C., Yeh, C. Y., Liu, K. L., Chao, Y. C., Lin, C. H., & Liu, C. S. (2026). Intranasal Administration of an Arginine‐Enriched Penetratin Peptide Confers Neuroprotection via Mitochondrial Functional Modulation in a Genetic Parkinson's Disease Model. CNS Neuroscience & Therapeutics, 32(8). https://doi.org/10.1002/cns.71108
Vancouver
Chang JC, Yeh CY, Liu KL, Chao YC, Lin CH, Liu CS. Intranasal Administration of an Arginine‐Enriched Penetratin Peptide Confers Neuroprotection via Mitochondrial Functional Modulation in a Genetic Parkinson's Disease Model. CNS Neuroscience & Therapeutics. 2026;32(8). doi:10.1002/cns.71108
BibTeX
@article{Chang2026,
author = {Chang, Jui-Chih and Yeh, Cheng-Yi and Liu, Kai-Li and Chao, Yi-Chun and Lin, Chin-Hsien and Liu, Chin-San},
title = {Intranasal Administration of an Arginine‐Enriched Penetratin Peptide Confers Neuroprotection via Mitochondrial Functional Modulation in a Genetic Parkinson's Disease Model},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {8},
doi = {10.1002/cns.71108}
}
EUVIMED